Vimarsana
Biggest News Aggregation in the World

Page 6 - Open Label Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Label Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Label Phase Today - Breaking & Trending Today

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks - Vimarsana News

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI - Vimarsana News

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

Investigational Onivyde (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022 - Vimarsana News

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022

Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022

United BioPharma gets FDA approval for phase 2 HIV drug trial - Vimarsana News

United BioPharma gets FDA approval for phase 2 HIV drug trial

United BioPharma says the FDA has approved a clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases. 

NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421 - Vimarsana News

NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421

/PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by...